Based on these findings that potentially connect mitochondrial antioxidant defense and cell cycle pathways, we hypothesized that downregulation of Trx2 via auranofin combined with CDK4/6 inhibition via palbociclib would be more effective than either agent alone to decrease mesothelioma cell growth. Here, CDK4 is linked to mesothelioma.